Clinical significance of tumor markers and an emerging perspective on colorectal cancer

• Published in: Cancer science Vol. 100; no. 2; pp. 195 - 199
• Main Authors: Yamashita, Keishi, Watanabe, Masahiko
• Format: Journal Article
• Language: English
• Published: Melbourne, Australia Blackwell Publishing Asia 01.02.2009; Blackwell
• Subjects: Biological and medical sciences; Biomarkers, Tumor - analysis; CA-19-9 Antigen - blood; Carcinoembryonic Antigen - blood; Colorectal Neoplasms - chemistry; Colorectal Neoplasms - diagnosis; Colorectal Neoplasms - therapy; Gastroenterology. Liver. Pancreas. Abdomen; Humans; Medical sciences; Prognosis; Review; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus; Tumors; Colonic disease; Rectal disease; Cancerology; Colorectal cancer; Digestive diseases; Intestinal disease; Tumoral marker; Malignant tumor; Cancer
• ISSN: 1347-9032; 1349-7006; 1349-7006
• DOI: 10.1111/j.1349-7006.2008.01022.x

Serum carcinoembryonic antigen (CEA) and CA19‐9, a carbohydrate antigen recognized by the monoclonal antibody NS19‐9, are commonly used as classical tumor markers in colorectal cancer (CRC) clinics. The roles of tumor markers include: (1) diagnostic screening (diagnostic markers); (2) prediction of prognosis after treatment (prognostic markers); and (3) judgment tools for treatment effect (surveillance markers). Tumor markers can be evaluated in serum, stools, or even in tissues depending on the clinical purpose. The American Society for Clinical Oncology recommends that CEA is the only marker of choice for monitoring the response of metastatic disease to systemic therapy at present. In the present paper, we are the first to review the clinical significance of the classical tumor markers CEA and CA19‐9 in serum, allowing for our original data, and present our view on the newly emerging biomarkers in CRC. Novel promising biomarkers for diagnostic, prognostic, and surveillance purposes are reviewed and considered, some of which are anticipated for further validation. For diagnostic markers, urine or serum might replace fecal samples in the near future. On the other hand, prognostic or predictive markers for treatment sensitivity may be identified from the molecular profiles of primary cancer tissues. Selection of patients who are sensitive to chemotherapy will reduce the number of patients who undergo harmful chemotherapy with no effectiveness. The optimal tumor markers would be generalized, easy to assess, and accurate, and such markers are eagerly anticipated to enable personalized tailored therapy for CRC patients. (Cancer Sci 2009; 100: 195–199)